Sangamo Therapeutics, Inc., a biotechnology company specializing in genetic therapies, has been navigating a challenging market environment. As of May 20, 2026, the company’s stock closed at $0.156, reflecting a significant decline from its 52-week high of $0.77 on September 28, 2025. The stock reached a 52-week low of $0.1 on May 7, 2026, indicating heightened volatility in its market performance.
Operating from Richmond, United States, Sangamo Therapeutics focuses on developing medications for patients with genetic diseases. Despite its innovative approach in the biotechnology sector, the company’s financial metrics reveal some challenges. The price-to-earnings ratio stands at -0.32, suggesting that the company is not currently generating profits. This is a common scenario for many biotech firms, which often invest heavily in research and development before achieving profitability.
The company’s market capitalization is approximately $60.86 million, underscoring its relatively small size within the health care sector. Sangamo Therapeutics is listed on the OTC Bulletin Board, a platform often used by smaller or emerging companies.
In the broader market context, Sangamo Therapeutics is part of the holdings of the Vanguard Total Stock Market ETF. This ETF experienced a modest decline earlier in the trading day, influenced by factors such as rising Treasury yields and increased oil prices. While the ETF has shown a modest gain over the year, the specific impact on Sangamo Therapeutics remains unclear beyond its inclusion in the ETF’s portfolio.
As of the latest available information, there are no new developments reported regarding Sangamo Therapeutics’ business activities or financial results. The company continues to focus on its core mission of advancing genetic therapies, despite the current market challenges.
